• Masimo SET® pulse oximeters detected approximately 10 times more true events than other “Next Generation” pulse oximeters studied.1,2
  • Researchers showed time to reliable oxygen saturation readings during neonatal resuscitation was approximately 50 seconds faster using Masimo SET® than using other pulse oximetry technologies.3
  • In a PACU, Masimo SET® had a greater than 50% reduction in false alarms compared to other pulse oximetry technology.4
  • In two NICU settings, Masimo SET®, coupled with changes in clinical practice, showed significantly reduced rates of severe retinopathy of prematurity (ROP) and decreased the need for laser treatment to 0%.5,6
  • In a study of 39,821 infants, CCHD screening sensitivity increased from 63% with physical exam alone to 83% with physical exam and Masimo SET® pulse oximetry.7
  • In a study of 122,738 infants, critical congenital heart disease (CCHD) screening sensitivity increased from 77% to 93% with the combined use of Masimo SET® and clinical assessment.8
  • On a post-surgical unit, rescue calls and ICU transfers were reduced by 65% and 48%, respectively, after the implementation of continuous surveillance monitoring with Masimo SET®.9

“I saw and was conquered. I was not able to defeat the Masimo SET® pulse oximeter using all the motion and low pulse tricks I know. This technology is most impressive and should be available in all oximeters.”

John Severinghaus, M.D.
Professor of Anesthesiology, Emeritus University of California, San Francisco

Clinical Studies: The Performance of Masimo SET®

 

CCHD Screening

  • When combined with clinical assessment, Masimo SET® improved critical congenital heart disease (CCHD) screening sensitivity to 93%10

Improved Critical Congenital Heart Disease Screening
Sensitivity vs. Clinical Assessment Alone

Improved Critical Congenital Heart Disease Screening  Sensitivity vs. Clinical Assessment Alone

Retinopathy of Prematurity

  •  Masimo SET®, coupled with changes in clinical practice, led to a significant reduction in rates of severe Retinopathy of Prematurity (ROP)11

Severe Retinopathy of Prematurity Rate

Severe Retinopathy of Prematurity Rate

Performance During Motion and Low Perfusion

  • Masimo SET® had 3% missed true alarms and 5% false alarms versus 43% and 28%, respectively, using competitor technology12*

*Results shown are calculated by combining sensitivity and specificity outcomes of machine-generated and volunteer-generated motion.

Performance During Motion and Low Perfusion

Learn More About Masimo SET®

 

References:

  1. 1.

    Hay WW. Reliability of conventional and new oximetry in neonatal patients. J of Perinatol, 2002;22:360-36.

  2. 2.

    Barker SJ. “Motion-Resistant” Pulse Oximetry: A comparison of new and old models. Anesth Analg. 2002;95(4):967-72.

  3. 3.

    Baquero H et al. Avoiding Hyperoxemia during Neonatal Resuscitation: Time to Response of Different SpO2 Monitors. Acta Paediatr. 2011 Apr;100(4):515-8.

  4. 4.

    Malviya S et al. False Alarms and Sensitivity of Conventional Pulse Oximetry Versus the Masimo SET® Technology in the Pediatric Postanesthesia Care Unit. Anesth Analg 2000; 90(6):1336-1340.

  5. 5.

    Castillo et al. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

  6. 6.

    Sola et al. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? 2003;111(2):339-345.

  7. 7.

    de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009;338:a3037.

  8. 8.

    Zhao et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet. 2014 Aug 30;384(9945):747-54.

  9. 9.

    Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.

  10. 10.

     Zhao et al. Lancet. 2014 Aug 30;384(9945):747-54.

  11. 11.

    Castillo et al. Acta Paediatr. 2011 Feb;100(2):188-92.

  12. 12.

    Shah et al. J Clin Anesth. 2012;24(5):385-91.

RESOURCES

 

Follow the link for available Masimo SET studies.

Masimo - Product Information Masimo SET

Product Information

Masimo - Production Information Masimo SET Reduced Cost of Care

Product Information

For professional use. See instructions for use for full prescribing information including indications, contraindications, warnings and precautions. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

PLCO-001785/PLM-10297C-0318